Abnormal involuntary movements induced by subthalamic nucleus stimulation in parkinsonian patients

Movement Disorders

Volumn 11, Issue 3, 1996, Pages 231-235

  Limousin, Patricia ^a   Pollak, Pierre ^a   Hoffmann, Dominique ^a   Benazzouz, Abdelhamid ^a   Perret, Jean Edmond ^a   Benabid, Alim Louis ^a  

^a UNIV GRENOBLE ALPES   (France)

Author keywords

Abnormal involuntary movements; Ballism; Parkinson's disease; Stimulation; Subthalamic nucleus

Indexed keywords

LEVODOPA;

ADULT; ARTICLE; CLINICAL ARTICLE; DYSKINESIA; DYSTONIA; ELECTRIC POTENTIAL; ELECTROSTIMULATION; FEMALE; HEMIBALLISM; HUMAN; HUMAN EXPERIMENT; LATENT PERIOD; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RISK; SUBTHALAMIC NUCLEUS; TECHNIQUE;

ANTIPARKINSON AGENTS; BROMOCRIPTINE; COMBINED MODALITY THERAPY; DOMINANCE, CEREBRAL; ELECTRIC STIMULATION THERAPY; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MOTOR ACTIVITY; MOTOR SKILLS; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; THALAMIC NUCLEI; TREATMENT OUTCOME;

EID: 0029913261     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870110303     Document Type: Article

References (20)

1. Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesion of the subthalamic nucleus. Science 1990;249:1436-1438.
2. Aziz TZ, Peggs D, Sambrook MA, Crossman AR. Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primates. Mov Disord 1991;6:288-292.
3. Aziz TZ, Peggs D, Argarwal E, Sambrook MA, Crossman AR. Subthalamic nucleotomy alleviates parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed primates. Br J Neurosurg 1992;6:575-582.
4. Benazzouz A, Gross C, Féger J, Boraud T, Bioulac B. Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur J Neurosci 1993;5:382-389.
5. Wichmann T, Bergman H, DeLong MR. The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism. J Neurophysiol 1994;72:521-530.
6. Limousin P, Pollak P, Benazzouz A, et al. Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995;345:91-95.
7. Klawans HL, Moses H, Nausieda PA, Bergan D, Weiner WJ. Treatment and prognosis of hemiballism. N Engl J Med 1976;295:1348-1350.
8. Buruma OJS, Lakke JPWF. Ballism. In: Vinken PJ, Bruyn GW, Klawans HL, eds. Handbook of clinical neurology, vol. 5. Amsterdam: Elsevier Science, 1986:369-380.
9. Dewey RB, Jankovic J. Hemiballism-hemichorea, clinical and pharmacologic findings in 21 patients. Arch Neurol 1989;46:862-867.
10. Shannon KM. Hemiballismus. Clin Neuropharmacol 1990; 13:413-425.
11. Carpenter MB, Whittier JR, Mettler FA. Analysis of choreoid hyperkinesia in the rhesus monkey, surgical and pharmacological analysis of hyperkinesia resulting from lesions in the subthalamic nucleus of Luys. J Comp Neurol 1950; 92:293-331.
12. Carpenter MB, Brittin GM. Subthalamic hyperkinesia in rhesus monkeys, effects of secondary lesions in red nucleus and brachium conjuntivum. J Neurophysiol 1958;21:400-413.
13. Hamada I, DeLong MR. Excitotoxic acid lesions of the primate subthalamic nucleus result in transient dyskinesias of the contralateral limbs. J Neurophysiol 1992;68:1850-1858.
14. Fahn S, Elton R. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent developments in Parkinson's disease; vol. II. Florham Park, NJ: MacMillan Healthcare Information, 1987:153-163.
15. Wichmann T, Bergman H, DeLong MR. The primate subthalamic nucleus. I. Functional properties in intact animals. J Neurophysiol 1994;72:494-506.
16. Agid Y, Bonnet AM, Signoret JL, Lhermitte F. Clinical, pharmacological, and biochemical approach of "onset- and end-of-dose" dyskinesias. Adv Neurol 1979;24:401-410.
17. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability Parkinson's disease: clinical aspects. In: Marsden CD, Fahn S, eds. Movement disorders. London: Butterworth, 1981: 96-122.
18. Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 1992;7:117-124.
19. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990;13:266-271.
20. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990;13:281-285.